Innoviva Inc (OQ:INVA)

Business Focus: Pharmaceuticals

Feb 29, 2024 04:05 pm ET

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.

Nov 01, 2023 04:15 pm ET

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Nov 01, 2023 04:05 pm ET

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular (IM) injection of ceftriaxone and oral azithromycin, a current global standard of care regimen. In th

Sep 19, 2023 08:30 am ET

Innoviva to Participate in the Cantor Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time.

Sep 18, 2023 08:00 am ET

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in A

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is now available in the United States for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

Aug 25, 2023 04:52 pm ET

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023.

Aug 02, 2023 04:05 pm ET

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Jul 13, 2023 10:26 am ET

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK, July 13, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Innoviva, Inc. (NASDAQ: INVA).

Jul 11, 2023 08:00 am ET

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Signs new $25 million credit agreement and extension of existing secured convertible credit agreement

Jun 06, 2023 04:05 pm ET

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12th, 2023 at 2:00 p.m. Pacific Time.

May 23, 2023 06:42 pm ET

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Innoviva Specialty Therapeutics is focused on delivering innovative therap

May 11, 2023 06:45 pm ET

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam, the first pathogen-targeted therapy being studied for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The study

May 09, 2023 04:32 pm ET

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the first quarter ended March 31, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Apr 28, 2023 05:30 pm ET

Innoviva Announces Retirement of Board Chairman

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members.

Apr 17, 2023 04:31 pm ET

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The sulbacta

Apr 17, 2023 09:00 am ET

Innoviva Stock Trading Halted Today

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has halted trading of Innoviva’s common stock.

Mar 13, 2023 06:24 pm ET

Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR).

Feb 28, 2023 04:10 pm ET

Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

Jan 10, 2023 03:05 pm ET

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

MARINA DEL REY, Calif., Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to the Company from the transaction

Nov 30, 2022 04:30 pm ET

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains. The Agency is currently planning to hold an advisory committee meeting to discuss this application. The target PDUFA date (or action d

Nov 09, 2022 04:05 pm ET

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022.

Oct 19, 2022 08:00 am ET

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the...

Oct 12, 2022 08:30 am ET

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Sep 08, 2022 07:00 am ET

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.

Aug 22, 2022 08:55 am ET

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer

Jul 27, 2022 04:05 pm ET

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022.

Jul 13, 2022 04:32 pm ET

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 millio

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC (“TRC”), which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc (Nasdaq: RPRX) for an upfront cash payment of approximately $282 million and a potential $50 million contingent sales-based milestone payment. Under the terms of the agreement, TRC also t

Jul 13, 2022 04:25 pm ET

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and...

Jul 11, 2022 09:17 am ET

Innoviva Completes Acquisition of Entasis Therapeutics

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.

Jul 11, 2022 07:32 am ET

Innoviva to Acquire La Jolla Pharmaceutical Company

Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and

Jul 11, 2022 07:30 am ET

Innoviva to Acquire La Jolla Pharmaceutical Company

Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and

Jul 08, 2022 08:35 am ET

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.

Jun 21, 2022 02:55 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations

NEW YORK, June 21, 2022 /PRNewswire/ --

May 24, 2022 06:36 pm ET

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

NEW YORK, May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning the proposed acquisition of the company by Innoviva, Inc. (NASDAQ: INVA). Stockholders will receive $2.20 for each share of Entasis Therapeutics Holdings stock that they hold. Innoviva currently owns approximately 60% of Entasis Therapeutics Holdings common stock. The transaction is valued at approximately $113 million and is expected to close in the third quarter of 2022.

May 24, 2022 04:04 pm ET

ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated...

May 24, 2022 02:09 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PCSB Financial Corporation (Nasdaq - PCSB), CynergisTek Inc. (NYSE American - CTEK), Entasis Therapeutics Holdi

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...

May 23, 2022 08:50 pm ET

SHAREHOLDER ALERT: Weiss Law Investigates Entasis Therapeutics Holdings Inc.

NEW YORK, May 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Entasis Therapeutics Holdings Inc. ("Entasis" or the "Company") (NASDAQ: ETTX) in connection with the proposed acquisition of the Company by Innoviva, Inc. (NASDAQ: INVA) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $2.20 in cash for each share of Entasis common stock owned. The transaction is valued at approximately $113 million.

May 23, 2022 08:30 am ET

Innoviva to Acquire Entasis Therapeutics

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash. Innoviva currentl

May 23, 2022 08:30 am ET

Innoviva to Acquire Entasis Therapeutics

Apr 27, 2022 05:11 pm ET

Innoviva Reports First Quarter 2022 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2022.

Mar 31, 2022 04:05 pm ET

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

MARINA DEL REY, Calif., March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company's $45 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva,

Mar 03, 2022 07:45 am ET

Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”). The size of the offering was increased from the previously announced offering size of $200 million. The Notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). The Company also granted the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from

Mar 02, 2022 07:30 am ET

Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced its intention to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2028 (the “Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). The Company also intends to grant the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $40 million

Feb 10, 2022 08:31 am ET

Thinking about buying stock in Marqeta, Innoviva, Seanergy Maritime, Peabody Energy, or Aridis Pharmaceuticals?

NEW YORK, Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, INVA, SHIP, BTU, and ARDS.

Feb 09, 2022 04:45 pm ET

Innoviva Reports Fourth Quarter 2021 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the fourth quarter and the year ended December 31, 2021.

Feb 09, 2022 03:16 pm ET

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

MARINA DEL REY, Calif., Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to the Company from the

Oct 27, 2021 04:05 pm ET

Innoviva Reports Third Quarter 2021 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the third quarter ended September 30, 2021.

Jul 28, 2021 04:05 pm ET

Innoviva Reports Second Quarter 2021 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the second quarter ended June 30, 2021.

May 20, 2021 09:40 am ET

Innoviva Announces Strategic Repurchase of GSK’s Equity Stake

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK’s equity stake in Innoviva, constituting approximately 32 million shares, or 32% of the outstanding common stock, at $12.25 per share, representing a 3% discount to the 5-day volume weighted average price of the Company’s common stock, for a total purchase price of $392 million.

May 05, 2021 04:05 pm ET

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2021 financial results and provided a business...

May 03, 2021 04:05 pm ET

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately...

Apr 28, 2021 04:05 pm ET

Innoviva Reports First Quarter 2021 Financial Results

Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2021.

Feb 03, 2021 04:05 pm ET

Innoviva Reports Fourth Quarter 2020 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020.

Jan 27, 2021 06:01 am ET

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs

MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to the Compan

Oct 28, 2020 04:30 pm ET

Innoviva Reports Third Quarter 2020 Financial Results

Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020.

Sep 09, 2020 06:45 pm ET

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

Sep 09, 2020 06:24 pm ET

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

Aug 28, 2020 08:00 am ET

Entasis Therapeutics Announces $25 Million Private Placement

Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitive agreement to sell...

Jul 29, 2020 04:05 pm ET

Innoviva Reports Second Quarter 2020 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020.

Jun 11, 2020 04:05 pm ET

Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35 million...

May 21, 2020 04:05 pm ET

Innoviva Names Pavel Raifeld as Chief Executive Officer

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant shareholder value. Mr. Raifeld replaces Geoff Hulme, who served as the Company’s principal executive officer since May 2018.

May 07, 2020 04:05 pm ET

Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update

Apr 29, 2020 04:05 pm ET

Innoviva Reports First Quarter 2020 Financial Results

Innoviva, Inc. (NASDAQ:INVA) ("Innoviva," or "the Company") today reported financial results for the first quarter ended March 31, 2020.

Apr 22, 2020 04:05 pm ET

Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva

Mar 31, 2020 04:05 pm ET

Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. As previously announced, the annual meeting will be held on Friday, April 24, 2020 at 10:00 a.m. Eastern Time. To be admitted to the annual meeting at

Mar 30, 2020 07:30 am ET

Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a vote in favor of the transaction by more than 99% of the Armata shareholders that voted, Armata has completed the closing of the second tranche under the Company's $25 million Securities Purchase Agreement with Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include res

Feb 27, 2020 09:36 am ET

GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults by the European Medicines Agency (EMA).

Feb 05, 2020 04:05 pm ET

Innoviva Reports Fourth Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2019.

Oct 30, 2019 04:05 pm ET

Innoviva Reports Third Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the “Company”) today reported financial results for the third quarter ended September 30, 2019.

Oct 02, 2019 09:17 am ET

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults. Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Jul 24, 2019 04:05 pm ET

Innoviva Reports Second Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ:INVA) (the Company) today reported financial results for the second quarter ended June 30, 2019.

May 02, 2019 12:18 pm ET

Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipta (FF/VI), in the treatment of patients living with uncontrolled asthma.

May 01, 2019 04:09 pm ET

Innoviva Reports First Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ:INVA) (the Company) today reported financial results for the first quarter ended March 31, 2019.

Feb 06, 2019 04:05 pm ET

Innoviva Reports Fourth Quarter 2018 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2018.

Feb 06, 2019 08:15 am ET

Report: Developing Opportunities within Xcel Energy, Empire State Realty Trust, Innoviva, Tyler Technologies, Tower International, and Nathan's Famous — Future Expectations, Projections Moving into 20

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Xcel Energy Inc. (NASDAQ:XEL), Empire State Realty Trust, Inc....

Nov 09, 2018 07:01 am ET

Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (

Nov 06, 2018 07:30 am ET

Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating F

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oil States International, Inc. (NYSE:OIS), Brightcove Inc. (NASDAQ:BCOV),...

Oct 31, 2018 04:05 pm ET

Innoviva Reports Third Quarter 2018 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter ended September 30, 2018.

Sep 21, 2018 07:30 am ET

Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

Aug 28, 2018 07:35 am ET

Report: Exploring Fundamental Drivers Behind Allscripts Healthcare Solutions, Dean Foods, Alder BioPharmaceuticals, Innoviva, Chegg, and TEGNA — New Horizons, Emerging Trends, and Upcoming Development

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), Dean Foods Company...

Jul 26, 2018 04:05 pm ET

Innoviva Reports Second Quarter 2018 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2018.

Jun 26, 2018 07:55 am ET

Recent Analysis Shows Church & Dwight Co., Innoviva, PTC Therapeutics, KBR, Murphy Oil, and F.N.B. Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church Dwight Co., Inc. (NYSE:CHD), Innoviva, Inc. (NASDAQ:INVA), PTC...

May 29, 2018 02:00 am ET

GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease (COPD). This is the first regulatory filing to be made in Japan for a triple COPD therapy in a single inhaler.

May 22, 2018 04:05 pm ET

Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value.

May 08, 2018 08:25 am ET

Research Report Identifies ILG, Innoviva, iRobot, KBR, KapStone Paper and Packaging, and Lumentum with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ILG Inc. (NASDAQ:ILG), Innoviva, Inc. (NASDAQ:INVA), iRobot Corporation...

Apr 26, 2018 08:00 am ET

Innoviva Reports First Quarter 2018 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the first quarter ended March 31, 2018.

Apr 24, 2018 12:55 pm ET

Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.

Apr 18, 2018 05:00 pm ET

Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one of the biggest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.1

Mar 08, 2018 03:00 am ET

GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

Mar 06, 2018 08:15 am ET

Report: Exploring Fundamental Drivers Behind Okta, Conduent, Innoviva, PRA Health Sciences, DDR, and Tenet Healthcare — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Conduent Inc. (NYSE:CNDT),...

Feb 14, 2018 04:00 am ET

GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (for the relief of symptoms and reduction of exacerbations, see section 5.1).

Feb 13, 2018 10:38 am ET

Sarissa Capital Reconstitutes Innoviva Board Of Directors

GREENWICH, Conn., Feb. 13, 2018 /PRNewswire/ -- Sarissa Capital Management LP announced today that Sarissa Capital has entered into an agreement with Innoviva, Inc. (NASDAQ: INVA) to reconstitute the entire board of directors as follows:

Feb 08, 2018 04:05 pm ET

Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited (GSK) during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.

Feb 08, 2018 01:40 pm ET

Innoviva, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Innoviva, Inc. (NASDAQ: INVA) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 5:00 PM Eastern Time.

Jan 26, 2018 04:00 am ET

GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

Dec 19, 2017 04:05 pm ET

Innoviva and Sarissa Implement Court Order

Innoviva, Inc. (the “Company” or “Innoviva”) (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates (together, “Sarissa”) in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017. Pursuant to the Court order, the Company has expanded the size of the Company’s Board of Directors (the “Board”) from six to eight members and appointed George Bickerstaff, III and Odysseas Kostas,

Nov 23, 2017 02:00 am ET

GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Approval of this sNDA means FF/UMEC/VI could be used by physicians to treat a wider population o

Nov 16, 2017 02:00 am ET

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

Nov 09, 2017 08:20 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna Inc. (NYSE:TGNA), Inpixon (NASDAQ:INPX), Honeywell...

Nov 01, 2017 07:00 am ET

GSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary Disease

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) fixed-dose combination, Anoro Ellipta (umeclidinium/vilanterol 62.5mcg/25mcg; UMEC/VI) and Stiolto Respimat (tiotropium/olodaterol 5mcg/5mcg; TIO/OLO), for symptomatic patients with chronic obstructive pulmonary disease (COPD). These data have been published today in Advances in Therapy1 and are

Sep 18, 2017 09:30 pm ET

Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

LONDON, Sept. 18, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing e

Apr 26, 2017 07:59 am ET

Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs

GREENWICH, Conn., April 26, 2017 /PRNewswire/ -- Sarissa Capital Management LP made the following statement regarding Innoviva, Inc. (NASDAQ: INVA):

Apr 21, 2017 07:59 am ET

Overwhelming Majority Of Non-GSK Shareholders Support Sarissa Capital And Not Innoviva Board And Management

GREENWICH, Conn., April 21, 2017 /PRNewswire/ -- Sarissa Capital Management LP made the following statement regarding Innoviva, Inc. (NASDAQ: INVA):

Apr 19, 2017 09:33 pm ET

Innoviva Reneges On Accepted Deal With Sarissa Capital

GREENWICH, Conn., April 19, 2017 /PRNewswire/ -- Sarissa Capital Management LP made the following statement regarding its nomination of a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) at its 2017 annual meeting to be held on April 20, 2017 at 8:30 a.m. EDT:

Apr 17, 2017 05:11 pm ET

Sarissa Capital States: Innoviva Already Appears To Renege On Cost Cuts; Innoviva Thinks Its Bad Corporate Governance Is Not A Problem

GREENWICH, Conn., April 17, 2017 /PRNewswire/ -- Sarissa Capital Management LP made the following statement regarding its nomination of a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) at its 2017 annual meeting to be held on April 20, 2017 at 8:30 a.m. EDT:

Apr 17, 2017 08:34 am ET

Sarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Conspicuous Absence Of Promises To Fix Bad Corporate Governance

Apr 13, 2017 11:29 am ET

Sarissa Capital Urges Shareholders Of Innoviva, Inc.: Follow The Recommendations Of ISS, Glass Lewis And Egan-Jones; Vote On The Gold Card For Sarissa Nominees

GREENWICH, Conn., April 13, 2017 /PRNewswire/ -- Sarissa Capital Management LP today issued the following letter to shareholders of Innoviva, Inc. (NASDAQ: INVA):

Apr 12, 2017 03:47 pm ET

Sarissa Capital Files Presentation In Proxy Contest With Innoviva

GREENWICH, Conn., April 12, 2017 /PRNewswire/ -- Sarissa Capital Management LP announced today that it filed a presentation with the Securities and Exchange Commission in connection with its intent to nominate a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) at its 2017 annual meeting to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia. The presentation, which is available on the SEC's website at http://www.sec.gov or on the website maintained by D.F. King & Co., Inc. at http://www.dfking.com/INVA, highlights that:

Apr 12, 2017 08:58 am ET

Egan-Jones Supports All Three Sarissa Capital Nominees For Innoviva Board

GREENWICH, Conn., April 12, 2017 /PRNewswire/ -- Sarissa Capital Management LP announced today that Egan-Jones, an influential independent proxy voting and corporate governance advisory firm, announced its support for all three Sarissa nominees to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) at its 2017 annual meeting to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia.

Apr 11, 2017 09:16 am ET

Sarissa Capital Is Concerned That Innoviva Will Waste Shareholder Money On Imprudent Acquisitions

GREENWICH, Conn., April 11, 2017 /PRNewswire/ -- Sarissa Capital Management LP today made the following statement in connection with its intent to nominate a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia.

Apr 10, 2017 04:55 pm ET

Sarissa Capital Compelled To Clarify Egregious Misstatements Made By Innoviva

GREENWICH, Conn., April 10, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") today made the following statement regarding the latest misleading statements made by Innoviva, Inc. (NASDAQ: INVA).

Apr 10, 2017 09:31 am ET

ISS Supports All Three Sarissa Capital Nominees For Innoviva Board

GREENWICH, Conn., April 10, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") announced today that Institutional Shareholder Services Inc. ("ISS"), the leading independent proxy voting and corporate governance advisory firm, supports ALL THREE of Sarissa's nominees to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia.

Apr 06, 2017 02:35 pm ET

Glass Lewis Supports Sarissa Capital's Nominees For Innoviva Board

GREENWICH, Conn., April 6, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") announced today that Glass Lewis, an influential and leading independent proxy voting and corporate governance advisory firm, announced its support for two of Sarissa's three nominees to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia.

Apr 05, 2017 09:01 pm ET

Lifshitz & Miller LLP Announces Investigation of BRF S.A., Innoviva, Inc., Panera Bread Company, PRA Group, Inc., Proteon Therapeutics, Inc., tronc, Inc. and Vuzix Corporation

NEW YORK, April 5, 2017 /PRNewswire/ --

Apr 04, 2017 09:37 am ET

Sarissa Capital Believes That Innoviva's Recent Statements Reinforce That Innoviva Is Being Run for the Benefit of Management and Not Shareholders

GREENWICH, Conn., April 4, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") today made the following statement in connection with its intent to nominate a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia.

Mar 29, 2017 04:13 pm ET

Sarissa Capital Responds To Innoviva's Many Misstatements

GREENWICH, Conn., March 29, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") today made the following statement in connection with its intent to nominate a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia, PA.

Mar 27, 2017 08:58 am ET

Sarissa Capital Files Presentation In Proxy Contest With Innoviva Highlighting Innoviva's Lack Of Shareholder Focus And Poor Corporate Governance

GREENWICH, Conn., March 27, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa") announced today that it filed a presentation with the Securities and Exchange Commission (the "SEC") in connection with its intent to nominate a minority slate to the Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at its 2017 annual meeting of stockholders to be held on April 20, 2017 at 8:30 a.m. EDT in Philadelphia, PA. The presentation is available on the SEC's website at http://www.sec.gov or on the website maintained by D.F. King & Co., Inc. at http://www.dfking.com/INVA.

Mar 13, 2017 09:30 am ET

Sarissa Capital Responds To Innoviva's Preemptive Launch Of Proxy Contest

GREENWICH, Conn., March 13, 2017 /PRNewswire/ -- Sarissa Capital Management LP ("Sarissa Capital") announced today that it intends to nominate a minority slate of three highly qualified independent candidates for election to the seven-member Board of Directors of Innoviva, Inc. (NASDAQ: INVA) ("Innoviva") at the 2017 Annual Meeting of Stockholders and has filed a Preliminary Proxy Statement with the Securities and Exchange Commission in connection therewith.

Jan 10, 2017 08:34 am ET

Ehave, Inc. Appoints New Members to its Board of Directors

Ted Witek, DrPH, Appointed as Chairman of the Board

Jan 10, 2017 08:34 am ET

Ehave, Inc. Appoints New Members to its Board of Directors

Ted Witek, DrPH, Appointed as Chairman of the Board

Nov 21, 2016 07:00 am ET

GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

LONDON, Nov. 21, 2016 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD). This follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018.

Nov 07, 2016 06:04 pm ET

Innoviva Set to Join the S&P SmallCap 600

NEW YORK, Nov. 7, 2016 /PRNewswire/ -- Innoviva Inc. (NASD: INVA) will replace Rofin-Sinar Technologies Inc. (NASD: RSTI) in the S&P SmallCap 600 after the close of trading on Wednesday, November 9. S&P SmallCap 600 constituent Coherent Inc. (NASD: COHR) acquired Rofin-Sinar Technologies in a deal completed today.

Jun 02, 2016 12:00 pm ET

Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD

LONDON, June 2, 2016 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipate

Jun 02, 2016 02:00 am ET

Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD

GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, long-acting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the

Jun 01, 2016 04:05 pm ET

Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.

May 24, 2016 05:59 am ET

Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'

GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the innovative Salford Lung Study (SLS) in Chronic Obstructive Pulmonary Disease (COPD). The study showed that Relvar® Ellipta® 100/25mcg (fluticasone furoate 'FF'/vilanterol 'VI' or 'FF/VI', known as Breo® Ellipta® in the United States) achieved a superior reduction in exacerbations versus usual care, in patients with COPD, in an everyday clinical practice setting. Usual care included long-acting muscarinic antagonists (LAMA), long-acting

May 18, 2016 12:21 pm ET

GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium

GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI') in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy.

May 18, 2016 12:20 pm ET

GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference

GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate airflow limitation receiving Breo® Ellipta® (fluticasone furoate/vilanterol or FF/VI 100/25mcg) achieved improvements in exacerbations compared with placebo. The second analysis demonstrated these patients

May 03, 2016 06:56 pm ET

Innoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11 at 8:40 a.m. PT, at the Wynn Las Vegas in Las Vegas.

Apr 28, 2016 04:05 pm ET

Innoviva Reports First Quarter 2016 Financial Results

Innoviva, Inc. (NASDAQ: INVA)

Apr 20, 2016 04:05 pm ET

Innoviva to Report First Quarter 2016 Financial Results on April 28

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2016 after market close on Thursday, April 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

Mar 01, 2016 04:05 pm ET

Innoviva to Present at the Cowen & Company 36th Annual Health Care Conference 2016

Innoviva, Inc. (NASDAQ: INVA) announced today that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, is scheduled to present at the Cowen & Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:40 a.m. EST. The conference will be held from March 7-9, 2016 in Boston, MA.

You are here

Innoviva Inc (OQ:INVA)

Business Focus: Pharmaceuticals